Catch up on today’s top five analyst upgrades with this list compiled by The Fly: 1. Atara Biotherapeutics (ATRA) upgraded to Overweight from Neutral at JPMorgan with analyst Anupam Rama saying the most recent U.S. physician survey showed “clear enthusiasm” for ATA188 despite the early stage of the Phase 1 results in progressive multiple sclerosis. 2. Lowe’s (LOW) upgraded to Outperform from Perform at Oppenheimer with analyst Brian Nagel saying the upgrade is “largely tactical in nature” and based on the prospects for a continued flow of funds into more cyclically focused equites as well as Lowe’s “now historically discounted valuation” versus that of Home Depot (HD). 3. BJ’s Wholesale (BJ) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Horvers making a risk/reward call as he sees potential upside to the consensus Q1 comp estimate of down 9%. 4. Pioneer Natural (PXD) upgraded to Overweight from Sector Weight at KeyBanc with analyst Leo Mariani expecting the company’s 2021 oil production to come in 1.4% above the high end of its guidance. 5. Ventas (VTR) upgraded to Outperform from Neutral at Baird and upgraded to Overweight from Underweight at KeyBanc. This list is just a portion of The Fly’s full analyst coverage. To see The Fly’s full Street Research coverage, (click here.):(http://thefly.com/streetResearch.php)
previous post
next post